Epithelial ovarian cancer is infiltrated by activated effector T cells co-expressing CD39, PD-1, TIM-3, CD137 and interacting with cancer cells and myeloid cells.
T-cell phenotype
high grade serous ovarian cancer (HGSOC)
ovarian cancer
tumor microenvironment (TME)
tumor-infiltrating lymphocytes (TIL)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
04
2023
accepted:
14
09
2023
medline:
2
11
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Despite predicted efficacy, immunotherapy in epithelial ovarian cancer (EOC) has limited clinical benefit and the prognosis of patients remains poor. There is thus a strong need for better identifying local immune dynamics and immune-suppressive pathways limiting T-cell mediated anti-tumor immunity. In this observational study we analyzed by immunohistochemistry, gene expression profiling and flow cytometry the antigenic landscape and immune composition of 48 EOC specimens, with a focus on tumor-infiltrating lymphocytes (TILs). Activated T cells showing features of partial exhaustion with a CD137 These data demonstrate that EOC is enriched in CD137
Identifiants
pubmed: 37868997
doi: 10.3389/fimmu.2023.1212444
pmc: PMC10585363
doi:
Substances chimiques
Hepatitis A Virus Cellular Receptor 2
0
Programmed Cell Death 1 Receptor
0
Leukocyte Common Antigens
EC 3.1.3.48
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1212444Informations de copyright
Copyright © 2023 Tassi, Bergamini, Wignall, Sant’Angelo, Brunetto, Balestrieri, Redegalli, Potenza, Abbati, Manfredi, Cangi, Magliacane, Scalisi, Ruggiero, Maffia, Trippitelli, Rabaiotti, Cioffi, Bocciolone, Candotti, Candiani, Taccagni, Schultes, Doglioni, Mangili and Bonini.
Déclaration de conflit d'intérêts
CBo: received research support from Intellia Therapeutics and is member of advisory boards/consultant/speaker for Molmed, Intellia, TxCell, Novartis, GSK, Allogene, Kite/Gilead, Miltenyi, Kiadis, QuellTX, Janssen. BS is an employee and shareholder of Intellia Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunotherapy. 2010 May;2(3):305-27
pubmed: 20635898
Br J Cancer. 2021 Mar;124(6):1138-1149
pubmed: 33402737
Clin Cancer Res. 2016 Feb 1;22(3):714-24
pubmed: 26384738
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
J Interferon Cytokine Res. 2005 Aug;25(8):435-43
pubmed: 16108726
Int J Med Sci. 2020 Oct 23;17(18):3200-3213
pubmed: 33173439
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875-80
pubmed: 20385810
Cancer Res. 2005 Jan 1;65(1):331-7
pubmed: 15665311
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Oncol Lett. 2019 May;17(5):4557-4565
pubmed: 30944645
Ann Oncol. 2020 Sep;31(9):1240-1250
pubmed: 32473302
BMC Cancer. 2017 Sep 20;17(1):657
pubmed: 28931370
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
J Interferon Cytokine Res. 1997 Jan;17(1):17-26
pubmed: 9041467
Cancers (Basel). 2022 Dec 21;15(1):
pubmed: 36612041
Oncol Rep. 2020 Dec;44(6):2610-2620
pubmed: 33125122
Gynecol Oncol Rep. 2017 Jun 27;21:78-80
pubmed: 28736741
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33452206
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Gynecol Oncol. 2018 Oct;151(1):10-17
pubmed: 30078505
Cancer Lett. 2021 May 28;506:55-66
pubmed: 33662493
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
JCO Precis Oncol. 2020 Jun 16;4:
pubmed: 32923884
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
APMIS. 2021 May;129(5):254-264
pubmed: 33455015
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Cancer Immunol Res. 2022 Nov 2;10(11):1326-1339
pubmed: 36095166
Nat Commun. 2018 Jul 13;9(1):2724
pubmed: 30006565
Nat Commun. 2019 Mar 25;10(1):1065
pubmed: 30911002
Am J Reprod Immunol. 2020 Jul;84(1):e13244
pubmed: 32294293
Oncoimmunology. 2015 Jan 23;4(3):e994446
pubmed: 25949921
Front Genet. 2021 Nov 15;12:760225
pubmed: 34868239
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Cancer Res. 2021 Nov 15;81(22):5706-5719
pubmed: 34561272
Clin Cancer Res. 2012 Dec 1;18(23):6497-508
pubmed: 23032745
Cancer Res. 2017 Feb 15;77(4):851-861
pubmed: 27979840
Gynecol Oncol. 2017 Mar;144(3):607-612
pubmed: 28065619
J Immunother Cancer. 2020 Dec;8(2):
pubmed: 33335029
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Nat Med. 2019 Jan;25(1):89-94
pubmed: 30510250
Ann Oncol. 2017 Mar 1;28(3):651-657
pubmed: 27864219
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Cancer Cell. 2019 Jun 10;35(6):885-900.e10
pubmed: 31185212
JAMA Oncol. 2017 Dec 1;3(12):e173290
pubmed: 29049607
Front Genet. 2020 Jul 17;11:705
pubmed: 32765584
Oncoimmunology. 2018 Sep 26;7(12):e1502905
pubmed: 30524900
Cell. 2018 Jun 14;173(7):1755-1769.e22
pubmed: 29754820
Nat Immunol. 2021 Aug;22(8):1030-1041
pubmed: 34312544
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Lancet Oncol. 2021 Sep;22(9):1275-1289
pubmed: 34363762
J Gynecol Oncol. 2018 Nov;29(6):e93
pubmed: 30207101
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
Front Immunol. 2021 Jul 22;12:699895
pubmed: 34367161
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
J Clin Invest. 2007 Oct;117(10):2834-46
pubmed: 17823660
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Front Immunol. 2022 Aug 08;13:943389
pubmed: 36003381
Haematologica. 2023 Jun 01;108(6):1530-1543
pubmed: 36200418
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
PLoS One. 2014 Nov 03;9(11):e111757
pubmed: 25365237
Cancer Immunol Immunother. 2019 Jan;68(1):121-130
pubmed: 30306202
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42
pubmed: 17652518
Gynecol Oncol. 2016 Mar;140(3):494-502
pubmed: 26721227
Eur J Immunol. 2021 Aug;51(8):1992-2005
pubmed: 34081326
Anticancer Res. 2013 Sep;33(9):3855-9
pubmed: 24023319
Gynecol Oncol. 2014 Jun;133(3):401-4
pubmed: 24878391
Cancer Immunol Immunother. 2019 Sep;68(9):1515-1526
pubmed: 31515669
J Immunother Cancer. 2014 Jun 18;2:16
pubmed: 24995129
Mol Cancer Res. 2021 Dec;19(12):1973-1979
pubmed: 34615692
Eur J Immunol. 2022 Jan;52(1):96-108
pubmed: 34505280
Front Genet. 2021 May 13;12:680413
pubmed: 34054929
Cancer Cell. 2021 Dec 13;39(12):1623-1642.e20
pubmed: 34739845
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
J Immunother Cancer. 2021 Oct;9(10):
pubmed: 34607898
Cancer Epidemiol. 2016 Feb;40:152-7
pubmed: 26724464
Sci Adv. 2021 Nov 12;7(46):eabi5790
pubmed: 34767446
Clin Cancer Res. 2012 Jun 15;18(12):3281-92
pubmed: 22553348
Ther Adv Med Oncol. 2020 Oct 31;12:1758835920967241
pubmed: 33193829